A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Oct 3, 2012
Trial Information
Current as of August 19, 2025
Unknown status
Keywords
ClinConnect Summary
We believe that the use of intravitreal corticosteroids post-operatively has the capacity to mitigate much of the residual swelling and retinal thickening that is seen after vitrectomy for epiretinal membranes. The unique pharmacokinetics of the sustained released dexamethasone implant (Ozurdex®) makes it an ideal delivery system to use post-vitrectomy for epiretinal membrane surgery. Its duration of action and its drug delivery characteristics over 6 months approximately match the post-operative time course of healing and remodeling in an edematous retina.
This is a prospective, multicent...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing vitrectomy surgery for a visually significant (≤ 20/50) idiopathic epiretinal membrane.
- • Central retinal thickness ≥ 250 μm.
- • Age more than 18 years old.
- • Decision makers able to give informed consent.
- • Females of child bearing potential must agree to use acceptable means of birth control for the duration of the study.
- Exclusion Criteria:
- • Secondary epiretinal membranes (ex: secondary to a retinal vein occlusion, etc.).
- • Any other macular pathology that could affect anatomic or functional results.
- • History of uveitis requiring intravitreal triamcinolone injection.
- • History of steroid-responsive glaucoma.
- • History of moderate or advanced glaucoma (cup to disc ratio ≥ 0.7).
- • IOP \> 23 mm Hg if untreated, or \> 21 mm Hg if treated with medication.
- • Pregnant or breast-feeding woman.
- • Unable to attend the scheduled follow-up appointments.
- • Patients with known hypersensitivity to any components of Ozurdex® or to other corticosteroids.
- • Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
About Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre is a leading academic health science organization located in Toronto, Canada, renowned for its commitment to advancing patient care through innovative research and education. As a prominent clinical trial sponsor, Sunnybrook integrates cutting-edge medical research with clinical practice, focusing on a wide range of health disciplines, including cancer care, trauma, and cardiovascular health. The center collaborates with various stakeholders, including academic institutions, healthcare providers, and industry partners, to facilitate the development of novel therapies and improve health outcomes. With a robust infrastructure and a dedicated team of researchers and clinicians, Sunnybrook plays a pivotal role in translating scientific advancements into tangible benefits for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Peter J Kertes, MD,CM,FRCSC
Principal Investigator
Sunnybrook Health Sciences Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials